ClinicalTrials.gg
CompletedNCT02308033SMART GIVESUpdated Jul 27, 2020Results posted

Multi-Center Study of New Medications to Treat Vaginal Infections

A Phase 3 interventional study of Metronidazole and Gel vehicle in Vaginal Infection, sponsored by Curatek Pharmaceuticals, LLC. Completed at 35 sites in United States. Open to female participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-07-27.

Sponsored by Curatek Pharmaceuticals, LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
12 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Vaginitis with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Vaginitis · United States.

Enrollment
13th of 33
204 · median 77
Started
2015
with 4 others
Phase 3
8 of 38
none open now
Registered
17th of 38
by date
Lead sponsor
3 of 38
Curatek Pharmaceuticals, LLC

Among the 38 studies in Vaginitis with a site in United States, this one is the 13th largest by enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2015, is one of 8 in phase 3, and was the 17th registered.

Vaginitis

98 studies on the registry are indexed under Vaginitis; 12 are open to participants now.

Browse Vaginitis studies →

Open to participants now

4 of the 38 studies in Vaginitis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Vaginitis studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 12 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Vaginitis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of metronidazole gel in the treatment of vaginal infections.

03

Conditions studied

  • Vaginal Infection

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A clinical diagnosis of vaginal infection that is confirmed by laboratory testing and:
  • Capable of providing written or assent
  • Currently not menstruating and not anticipating menses during treatment
  • If heterosexually active, subject must be for ≥ 1 year, surgically sterile, or practicing an acceptable form of
  • Negative pregnancy test
  • Other criteria as identified in the protocol

Exclusion criteria

Exclusion Criteria:

  • Other infectious causes of vulvovaginitis
  • Subject has recently used, or is expected to require the concomitant use of prohibited medications/products
  • Nursing mother
  • Use of any drug within 30 days of enrollment
  • History of to any ingredient/component of the formulations
  • Other criteria as identified in the protocol
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
204 participants (actual)

Study arms

  • Active comparator
    Metronidazole vaginal gel

    One applicator full at bedtime

    Drug: Metronidazole

  • Placebo comparator
    Gel vehicle

    One applicator full at bedtime

    Drug: Gel vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit

    The percentage of participants with clinical cure in each arm was compared. Clinical cure of bacterial vaginosis is defined as 1. discharge has returned to normal/physiologic, 2. the whiff test is negative for any amine "fishy" odor, 3. the saline wet mount is \<20% clue cells

    Time frame: 7-14 days after beginning treatment

Secondary outcomes

  1. Improvement of BV Clue Cells

    Clue cells on wet mount were assessed and categorized as absent (\<20%) or present (\>=20%). Absence of clue cells is associated with improvement. The comparison was for percentage between arms for clue cells absent (\<20%).

    Time frame: 7-14 days after beginning treatment

  2. Microbiologic Improvement/Cure

    For bacterial vaginosis (BV), Gram stain Nugent scores are catergized as normal (0 to 3), intermediate (4 to 6) or BV (7 to 10). Normal scores are associated with BV microbiologic cure. The percentage of participants with normal scores were compared between treatments.

    Time frame: 7-14 days after beginning treatment

  3. Number of Participants Reporting Complete Resolution of Symptoms by Test of Cure Visit

    Subjects reported if symptoms completely resolved and the date of resolution. The percentage of participants reporting complete resolution of symptoms was compared between arms.

    Time frame: 7-14 days after beginning treatment

  4. Number of Participants With Treatment Emergent Adverse Events

    Adverse events were collected at study visits, from subject diaries and from spontaneous reports

    Time frame: Any time during study participation (up to 30 days)

07

Results

Posted Jul 27, 2020

Participant flow

Participant flow — Overall Study
MilestoneMetronidazole Vaginal GelGel Vehicle
Started102102
Completed7683
Not completed2619
Withdrew: Normal gram stain at baseline1310
Withdrew: Positive for std at baseline74
Withdrew: Lost to follow-up65

Outcome measures

PrimaryClinical Cure as Assessed by the Investigator at the Test-of-cure Visit

The percentage of participants with clinical cure in each arm was compared. Clinical cure of bacterial vaginosis is defined as 1. discharge has returned to normal/physiologic, 2. the whiff test is negative for any amine "fishy" odor, 3. the saline wet mount is \<20% clue cells

Time frame:
7-14 days after beginning treatment
Reported as:
Count of participants · Participants
Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit
ParticipantsMetronidazole Vaginal GelGel Vehicle
Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit4718
Statistical analysis
  • Metronidazole Vaginal Gel vs Gel Vehicle · Chi-squared, Corrected · p = <0.001
SecondaryImprovement of BV Clue Cells

Clue cells on wet mount were assessed and categorized as absent (\<20%) or present (\>=20%). Absence of clue cells is associated with improvement. The comparison was for percentage between arms for clue cells absent (\<20%).

Time frame:
7-14 days after beginning treatment
Reported as:
Count of participants · Participants
Improvement of BV Clue Cells
ParticipantsMetronidazole Vaginal GelGel Vehicle
Clue cells absent5219
Clue cells present1758
Data missing76
Statistical analysis
  • Metronidazole Vaginal Gel vs Gel Vehicle · Chi-squared, Corrected · p = <0.001
SecondaryMicrobiologic Improvement/Cure

For bacterial vaginosis (BV), Gram stain Nugent scores are catergized as normal (0 to 3), intermediate (4 to 6) or BV (7 to 10). Normal scores are associated with BV microbiologic cure. The percentage of participants with normal scores were compared between treatments.

Time frame:
7-14 days after beginning treatment
Reported as:
Count of participants · Participants
Microbiologic Improvement/Cure
ParticipantsMetronidazole Vaginal GelGel Vehicle
Normal Nugent score387
Intermediate Nugent score1611
BV Nugent score1559
Not taken76
Statistical analysis
  • Metronidazole Vaginal Gel vs Gel Vehicle · Chi-squared, Corrected · p = <0.001
SecondaryNumber of Participants Reporting Complete Resolution of Symptoms by Test of Cure Visit

Subjects reported if symptoms completely resolved and the date of resolution. The percentage of participants reporting complete resolution of symptoms was compared between arms.

Time frame:
7-14 days after beginning treatment
Reported as:
Count of participants · Participants
Number of Participants Reporting Complete Resolution of Symptoms by Test of Cure Visit
ParticipantsMetronidazole Vaginal GelGel Vehicle
Number of Participants Reporting Complete Resolution of Symptoms by Test of Cure Visit4332
Statistical analysis
  • Metronidazole Vaginal Gel vs Gel Vehicle · Chi-squared, Corrected · p = 0.034
SecondaryNumber of Participants With Treatment Emergent Adverse Events

Adverse events were collected at study visits, from subject diaries and from spontaneous reports

Time frame:
Any time during study participation (up to 30 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events
ParticipantsMetronidazole Vaginal GelGel Vehicle
Number of Participants With Treatment Emergent Adverse Events4231

Adverse events

Collected over Adverse events were collected over the entire course of the study (up to 30 days after beginning treatment).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Metronidazole Vaginal Gel0/96 (0%)0/96 (0%)25/96 (26%)
Gel Vehicle0/97 (0%)0/97 (0%)10/97 (10.3%)
Most frequent other events
Most frequent other events
EventMetronidazole Vaginal GelGel Vehicle
Vulvovaginal pruritisReproductive system and breast disorders8/966/97
Vulvovaginal candidiasisInfections and infestations7/961/97
Vulvovaginal mycotic infectionInfections and infestations5/961/97
HeadacheNervous system disorders5/962/97

Baseline characteristics

modified intent-to-treat (mITT) population includes all subjects randomized to treatment and administered at least one dose of study drug. In addition, subjects must have a Nugent score of 4 or more on Baseline visit Gram stain slide.

Age, Continuous
Age, Continuous(years)Metronidazole Vaginal GelGel VehicleTotal
Mean33.1 ± 8.7635.8 ± 10.4834.5 ± 9.76
Sex: Female, Male
Sex: Female, Male(Participants)Metronidazole Vaginal GelGel VehicleTotal
Female7683159
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Metronidazole Vaginal GelGel VehicleTotal
Hispanic or Latino9918
Not Hispanic or Latino6774141
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Metronidazole Vaginal GelGel VehicleTotal
American Indian or Alaska Native101
Asian022
Native Hawaiian or Other Pacific Islander011
Black or African American474592
White253257
More than one race336
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Metronidazole Vaginal GelGel VehicleTotal
United States7683159
08

Study locations

35 sites
  • University of Alabama
    Birmingham, Alabama 35294, United States
  • MomDoc Womens Health Research
    Scottsdale, Arizona 85251, United States
  • NEA Baptist Clinic
    Jonesboro, Arkansas 72401, United States
  • Gossmont Center for Clinical Research
    La Mesa, California 91942, United States
  • Genesis Center for Clinical Research
    San Diego, California 92103, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • Downtown Women's Health Care
    Denver, Colorado 80209, United States
  • Red Rocks Ob/Gyn
    Lakewood, Colorado 80228, United States
  • Women's Health CT Ob/Gyn
    Bridgeport, Connecticut 06606, United States
  • Segal Institute for Clinical Research
    North Miami, Florida 33161, United States
  • Discovery Clinical Research
    Plantation, Florida 33324, United States
  • Georgia Regents University
    Augusta, Georgia 30912, United States
  • Atlanta North Gynecology
    Roswell, Georgia 30075, United States
  • Mount Vernon CLinical Research
    Sandy Springs, Georgia 30328, United States
  • Rosemark Womens Care Specialists
    Idaho Falls, Idaho 83404, United States
  • Women's Health Practice
    Champaign, Illinois 61802, United States
  • Women's Healthcare Specialists, PC
    Kalamazoo, Michigan 49009, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Women's Clinic of Lincoln
    Lincoln, Nebraska 68510, United States
  • Legacy Women's Health
    Las Vegas, Nevada 89123, United States
  • R. Garn Mabey Jr., MD Gynecology
    Las Vegas, Nevada 89128, United States
  • Lawrence Ob/Gyn Clinical Research LLC
    Lawrenceville, New Jersey 08648, United States
  • Women's Health Research Center
    Plainsboro, New Jersey 08536, United States
  • Suffolk OB/GYN
    Port Jefferson, New York 11777, United States
  • East Carolina Women's Center
    New Bern, North Carolina 28562, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Radiant Research
    Columbus, Ohio 43212, United States
  • Drexel University
    Philadelphia, Pennsylvania 19102, United States
  • Philapelphia Clinical Research, LLC
    Philadelphia, Pennsylvania 19114, United States
  • Magee-Womens Hospital of UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • James T. Martin, MD
    North Charleston, South Carolina 29406, United States
  • The Jackson Clinic
    Jackson, Tennessee 38305, United States
  • TMC Life Research, Inc.
    Houston, Texas 77054, United States
  • Harborview Medical Center
    Seattle, Washington 98104, United States
  • Women's Clinical Research Center
    Seattle, Washington 98105, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2015 to primary completion in Jun 2017, 24 months.

Results were first posted in Jul 2020, 3 years 1 month after primary completion. A results delay was requested in Jun 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2014
First posted
Dec 4, 2014
StartActual
Jun 2015
Primary completionActual
Jun 2017
CompletionActual
Jun 2017
Results delay requested
Jun 26, 2018
Results first posted
Jul 27, 2020
Last update
Jul 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02308033
Lead sponsor
Curatek Pharmaceuticals, LLC
Responsible party
Sponsor
First posted
Dec 4, 2014
Start date
Jun 2015
Primary completion
Jun 2017
Completion
Jun 2017
Results posted
Jul 27, 2020
Last update
Jul 27, 2020

Study contacts

Robert J Borgman, Ph.D.
study director · Curatek Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metronidazole

Start the discussion